Scholarlink

Background <p>Management of hemodynamically significant patent ductus arteriosus (hsPDA) in neonates remains controversial, with wide variation in practice among neonatologists and pediatric cardiologists.</p> Methods <p>An IRB-approved anonymous 12-item survey assessing hsPDA screening, treatment preferences, and perceived risks and benefits was distributed to over 5,000 U.S. providers. Responses were statistically analyzed using standard parameters.</p> Results <p>A total of 462 completed surveys were analyzed (35% cardiologists, 64% neonatologists). Most providers-initiated PDA screening based on clinical condition. Medical therapy was the preferred first-line treatment. Nearly one-third favored conservative management when echocardiographic hsPDA was present with minimal clinical concern, while others delayed intervention beyond the neonatal period. Pediatric cardiologists were more likely than neonatologists to believe PDA closure reduces morbidity and mortality, although most providers still elected to treat hsPDA. Neonatologists favored medical and percutaneous approaches over surgery.</p> Conclusion <p>Significant inter-specialty variation persists in hsPDA management, highlighting the need for standardized, clinically integrated approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Universal practice based management of patent ductus arteriosus in premature neonates in 2025: BRONX PDA protocol and BRONX clinical scoring system (BCSS)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Priscila Lisboa,
  • Jinal Gada,
  • Antonia Gaudig,
  • Adithya Sivakumar,
  • Shantanu Rastogi,
  • Elena N. Kwon,
  • Melissa Fazzari,
  • Nicole Sutton,
  • Manoj Gupta

摘要

Background

Management of hemodynamically significant patent ductus arteriosus (hsPDA) in neonates remains controversial, with wide variation in practice among neonatologists and pediatric cardiologists.

Methods

An IRB-approved anonymous 12-item survey assessing hsPDA screening, treatment preferences, and perceived risks and benefits was distributed to over 5,000 U.S. providers. Responses were statistically analyzed using standard parameters.

Results

A total of 462 completed surveys were analyzed (35% cardiologists, 64% neonatologists). Most providers-initiated PDA screening based on clinical condition. Medical therapy was the preferred first-line treatment. Nearly one-third favored conservative management when echocardiographic hsPDA was present with minimal clinical concern, while others delayed intervention beyond the neonatal period. Pediatric cardiologists were more likely than neonatologists to believe PDA closure reduces morbidity and mortality, although most providers still elected to treat hsPDA. Neonatologists favored medical and percutaneous approaches over surgery.

Conclusion

Significant inter-specialty variation persists in hsPDA management, highlighting the need for standardized, clinically integrated approaches.